The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: Results of two phase 3 studies

Raburn M. Mallory1 | Jing Yu1 | Sachiko Kameo2 | Michio Tanaka2 | Ki Rito3 | Yohji Itoh2 | Filip Dubovsky1

Background: Quadrivalent live attenuated influenza vaccine (Q/LAIV) has not been assessed in Japanese children.

Objectives: Evaluate safety and efficacy of Q/LAIV in Japanese children.

Patients/methods: Two phase 3 studies were conducted in the 2014-2015 influenza season. Study 1 was an open-label, uncontrolled single arm, multicenter study of Q/LAIV safety in subjects aged 2-6 years. Study 2 was a randomized, double-blind, placebo-controlled multicenter study of Q/LAIV safety and efficacy; subjects aged 7-18 years were randomized 2:1 to receive Q/LAIV or placebo. Primary efficacy endpoint was laboratory-confirmed symptomatic influenza infection caused by vaccine-matched strains; secondary endpoint evaluated efficacy against all strains regardless of match. Both studies reported solicited symptoms, adverse events (AEs), and serious AEs.

Results: In Study 1, 100 subjects received Q/LAIV. In Study 2, 1301 subjects received Q/LAIV (n = 868) or placebo (n = 433). Treatment-emergent AEs occurred in 42% of subjects in Study 1, and in 24.3% of subjects in the Q/LAIV arm and in 25.9% of subjects in the placebo arm in Study 2. In Study 2, a single infection by a vaccine-matched strain was reported in the placebo arm, resulting in a vaccine efficacy estimate of 100% (95% CI: −1875.3, 100.0); efficacy for all strains regardless of match to the vaccine was 27.5% (95% CI: 7.4, 43.0).

Conclusions: Quadrivalent live attenuated influenza vaccine did not meet its primary efficacy endpoint as only a single infection by a vaccine-matched strain was detected; however, efficacy for the secondary endpoint, all strains regardless of match, was achieved. Q/LAIV was generally well tolerated in the Japanese pediatric population.

Keywords: Japan, LAIV, pediatric, seasonal influenza
Seasonal influenza affects an estimated 5%-10% of adults and 20%-30% of children worldwide. In Japan alone, it is estimated that over 10 million people are infected with the influenza virus annually. The global burden of influenza is substantial, and the World Health Organization estimates that influenza causes 3-5 million cases of severe illness and 300 000-500 000 deaths annually. Children are at high risk of developing serious complications from influenza such as pneumonia and secondary bacterial infections, and on a global level, influenza is associated with 10% of respiratory hospitalizations in children under 18 years old.

Influenza prevention is particularly important in those under 18 years of age, as children have the highest influenza attack rates and are key transmitters of influenza in the community as they can shed a greater amount of virus for longer periods of time in comparison with adults. In Japan, children have traditionally been vaccinated against influenza using trivalent inactivated influenza vaccines (TIVs) consisting of 3 influenza strains: two A strains and one B strain. However, 2 antigenically distinct lineages of influenza B (Victoria and Yamagata) commonly cocirculate in an influenza season. As Global Health Authorities have had limited success in selecting the B strain for trivalent vaccines that match the predominant circulating B strains, it has been suggested that a switch from TIV to a quadrivalent vaccine could reduce the incidence of influenza infection.

The intranasally administered quadrivalent live attenuated influenza vaccine (Q/LAIV) contains 4 virus strains: two type A strains (A/H1N1 and A/H3N2), and two type B strains: one from each of the Victoria and Yamagata lineages. Q/LAIV is currently used in North America and several countries in Europe, including the United Kingdom, which has implemented a national pediatric vaccination program using Q/LAIV. Although multiple studies have documented the safety and efficacy of Q/LAIV among children in countries outside Japan, Q/LAIV has not previously been assessed in Japanese children.

Here, we report the results of two phase 3 clinical trials of Q/LAIV in Japan: an open-label study of the safety and tolerability of Q/LAIV among Japanese children aged 2-6 years, and a randomized, double-blind, placebo-controlled study of the safety and efficacy of Q/LAIV among Japanese children aged 7-18 years.

2 | METHODS

2.1 | Study design

The first study (Study 1) was a phase 3 open-label, uncontrolled, multicenter study (ClinicalTrials.gov identifier: NCT02269488), which was conducted across 3 centers in Japan during the 2014-2015 influenza season to evaluate the safety and tolerability of Q/LAIV among Japanese children aged 2-6 years. The second study (Study 2) was a phase 3 randomized, double-blind, placebo-controlled multicenter study (ClinicalTrials.gov identifier: NCT02269475), which was conducted across 49 centers in Japan during the same influenza season to evaluate the safety and efficacy of Q/LAIV among Japanese children aged 7-18 years.

Both studies were performed in accordance with the principles of the Declaration of Helsinki, which are consistent with the International Conference on Harmonization (ICH)/Good Clinical Practice (GCP) and applicable regulatory requirements, and the AstraZeneca policy on Bioethics and Human Biological Samples. Both protocols were approved by the Institutional Review Board (IRB) of each study center, and all participants and/or legal representatives provided written informed consent.

2.2 | Vaccine

Each dose of LAIV contained $10^{7.0±0.5}$ FFU of each of the 4 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strains (A/H1N1; A/California/7/2009, A/H3N2; A/Texas/50/2012; B/Brussels/60/2008 [Victoria lineage], and B/Massachusetts/2/2012 [Yamagata lineage]). The clinical trial material used in the study was tested for potency, at the time it was released for clinical use using the same FDA/EMA approved methods that are used to release the commercially distributed vaccine. To ensure that the vaccine continued to meet its potency requirements, the vaccine was shipped and distributed to sites in Japan using validated shipping methods.

2.3 | Patients

2.3.1 | Study 1

The study planned to enroll approximately 100 subjects aged 2-6 years to assess the safety and tolerability of Q/LAIV. All subjects received an initial intranasal administration of 0.2 mL (0.1 mL per nostril) of vaccine, while subjects not previously vaccinated against seasonal influenza received a second dose after an interval of at least 4 weeks. Healthy subjects and those with chronic underlying medical conditions including mild-to-moderate asthma were included, provided the subject had not been hospitalized in the previous year. Subjects with asthma were included in this study and in Study 2 (below) based on the demonstrated safety and efficacy of LAIV in this population, and as these subjects are included in the indicated populations who can receive Q/LAIV in Europe and Canada.

2.3.2 | Study 2

This double-blind study planned to enroll 1008 subjects aged 7-18 years to assess the safety and efficacy of Q/LAIV. Subjects were randomized (2:1) to receive Q/LAIV or placebo via intranasal administration. Subjects received an intranasal administration of 0.2 mL (0.1 mL per nostril). Subjects aged 7-8 years not previously vaccinated against seasonal influenza received a second dose after an interval of at least 4 weeks. Consistent with Study 1, healthy subjects and those with chronic underlying medical conditions were
2.3.3 Determination of analysis set

In both Study 1 and Study 2, safety was assessed using the safety population, which included all subjects who received any amount of investigational product. For the safety population, subjects were analyzed per the treatment they received for the first dose. The per-protocol (PP) population was used for efficacy assessments in Study 2, and included all subjects who had no important protocol deviations, received the first and second dose of study vaccine or placebo per protocol, and were followed up for qualifying symptoms for influenza until the end of the influenza season.

2.4 Endpoints

2.4.1 Safety and tolerability

In both Study 1 and Study 2, solicited symptoms were collected for 14 days post-vaccination and included the following: fever ≥100.4°F (38.0°C) by any route, runny/stuffy nose, sore throat, cough, headache, generalized muscle aches, decreased activity level or tiredness/weakness, and decreased appetite. Adverse events (AEs), including treatment-emergent adverse events (TEAEs), were monitored for 28 days post-vaccination, and if patients received 2 doses of vaccine, they were monitored through the last dose. Serious adverse events (SAEs) were monitored from the time of informed consent through the last study contact with the subject.

2.4.2 Efficacy

In Study 2, the primary efficacy endpoint was laboratory-confirmed symptomatic influenza infection (modified influenza-like illness per the Centers for Disease Control [mCDC-ILI]) caused by any community-acquired wild-type strains matched to the vaccine. The secondary efficacy endpoint was laboratory-confirmed symptomatic influenza infection (mCDC-ILI) caused by any community-acquired wild-type strains regardless of match to the vaccine. Modified CDC-ILI was defined as increased temperature ≥100°F (37.8°C) (oral or equivalent) plus the presence of cough, sore throat, or runny nose/nasal congestion occurring on the same or consecutive days. Nasal swabs were evaluated for influenza using a polymerase chain reaction-based test, and genotyping, subtyping, and sequencing were performed. Isolates were categorized as vaccine-like (matched) or non-vaccine-like (mismatched) using genetic sequence alignment to reference strains for which a determination of match or mismatch was publicly available from the US CDC or other World Health Organization collaborating centers. For both efficacy endpoints, the influenza infection rate in Q/LAIV recipients was compared to that in placebo recipients during the influenza surveillance period and at least 14 days after the last administered vaccination.

2.5 Statistical analyses

Categorical data were summarized by the number and percentage of subjects falling within each category, and continuous variables were summarized using descriptive statistics including mean, standard error or deviation, median, minimum, and maximum.

The primary and secondary efficacy endpoints evaluated vaccine efficacy, that is, the risk reduction of influenza infection in Q/LAIV recipients compared to placebo recipients calculated as one minus the ratio of the infection rates. Statistical comparison was made by constructing 2-sided 95% confidence intervals (CI) for the efficacy estimate, and the CI was estimated by an exact conditional method conditioning on the total number of cases, which followed a Poisson assumption. If the lower bound of the 95% CI of vaccine efficacy was >0%, then the efficacy of Q/LAIV was demonstrated.

In Study 1 and Study 2, all safety evaluations were descriptive in nature, and in Study 2, safety evaluations were provided by the dose number and by treatment group. AEs and TEAEs were summarized by system organ class (SOC) and preferred term (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) version 17.1.

In both studies, statistical analysis was performed by Quintiles Transnational Japan K.K. in Japan. All analyses were conducted using Statistical Analysis System (SAS) version 9.2.

3 RESULTS

3.1 Study subjects: Study 1

All 100 enrolled Japanese children aged 2-6 years completed the study and were included in the safety analysis. The mean (SD) age of subjects was 4.2 (±1.4) years and male subjects accounted for 45.0% (45/100) of the population (Table 1). Of the 100 subjects, 25.0% (25/100) had preexisting medical conditions; the most frequent conditions were asthma (14%), allergic rhinitis (5%), and dermatitis (5%). A majority of the 100 subjects enrolled had previously received an influenza vaccination (94.0%, 94/100), and thus received a single dose of Q/LAIV. The remaining 6.0% (6/100) of subjects who had not been previously vaccinated received 2 doses of vaccine.

TABLE 1 Study 1 subject demographics (safety population, aged 2-6 y)

| Characteristics                        | Q/LAIV (n = 100) |
|----------------------------------------|-----------------|
| Age (y), mean (SD)                     | 4.2 (1.4)       |
| Male, n (%)                            | 45 (45.0)       |
| Number of doses of study vaccine received, n (%) |                |
| One                                    | 94 (94.0)       |
| Two                                    | 6 (6.0)         |
| Preexisting medical condition          |                 |
| Yes, n (%)                             | 25 (25.0)       |

Q/LAIV, quadrivalent live attenuated influenza vaccine; SD, standard deviation.
3.2  |  Study subjects: Study 2

A total of 1369 Japanese children aged 7-18 years were enrolled in Study 2. Of these, 1301 subjects were randomized to Q/LAIV (868) or placebo (433) with a 2:1 ratio at 49 study centers in Japan. Sixty-eight subjects were not randomized, primarily because randomization had closed after they were screened. All 1301 randomized subjects were included in the safety analysis.

The mean (SD) age of subjects was 11.0 (±3.0) years in the Q/LAIV group and 10.8 (±2.8) years in the placebo group (Table 2). 32.5% (282/868 subjects) in the Q/LAIV group and 28.4% (123/433 subjects) in the placebo group had preexisting medical conditions. The most frequent preexisting conditions in the Q/LAIV group and placebo group were allergic rhinitis (16.6% vs 15.5%), asthma (5.5% vs 4.8%), and seasonal allergy (3.8% vs 3.7%), respectively. A history of prior vaccination was reported in 90.8% (788/868) of subjects in the Q/LAIV group and 89.1% (386/433) of subjects in the placebo group. Most subjects (1297) completed the study, and 1279 subjects were included in the PP population.

3.3  |  Safety and tolerability

3.3.1  |  Solicited symptoms

In Study 1, the overall incidence of solicited symptoms was 57.0% (57/100 subjects). The most common solicited symptoms (≥5%) were runny/stuffy nose (51.0%), cough (34.0%), fever ≥100.4°F (38.0°C) (10.0%), and sore throat (7.0%; Table 3). In Study 2, the overall incidence of subjects with solicited symptoms was 41.7% (362/868) in the Q/LAIV group and 40.6% (176/433 subjects) in the placebo group. There were no notable differences in the incidence of solicited symptoms between the placebo and active arm of the study. The most common solicited symptoms (≥5% in either group) were runny/stuffy nose (33.2%), cough (12.4%), sore throat (10.1%), and headache (9.6%) in the Q/LAIV group, and runny/stuffy nose (27.7%), cough (15.9%), sore throat (14.1%), and headache (8.5%) in the placebo group (Table 4). The incidence rates for individual symptoms were similar between groups, with the exception of a slightly higher incidence rate of runny/stuffy nose in the Q/LAIV group (rate difference: 5.5%, 95% CI: 0.1, 10.6).

3.3.2  |  Adverse events

In Study 1, during the 28 days after the first vaccination, TEAEs were noted in 42.0% (42/100) of subjects. Two of 6 subjects (33.3%) without previous influenza vaccination who received 2 doses of the vaccine experienced TEAEs during the 28 days after the second vaccination, and all TEAEs were mild in intensity (Table 5). The only TEAE reported at a rate ≥5% was nasopharyngitis (13.0%), and no febrile convulsions were reported.

During the study, no SAEs were reported, and no discontinuations of the investigational product (IP) due to an AE were reported. Two TEAEs, abdominal pain, and diarrhea were reported in one subject after the first dose and were considered by the investigator to be related to the IP. One significant AE was reported as follows: a non-serious case of erythema multiforme occurred in a 6-year-old male subject with a history of previous influenza vaccination and without any medical history at day 26 after Q/LAIV administration. The TEAE was confirmed to be mild in intensity, not related to vaccination in terms of causality and resolved by day 51.

In Study 2, the incidence of TEAEs was 24.3% (211/868) in the Q/LAIV group and 25.9% (112/433) in the placebo group, with no
obvious differences in the profile of TEAEs between the 2 groups. The incidence of mild TEAEs was 21.4% (186/868) in the Q/LAIV group and 22.9% (99/433) in the placebo group, while moderate TEAEs were reported in 2.9% (25/868) of subjects in the Q/LAIV group and 3.0% (13/433) of subjects in the placebo group. No severe TEAEs were noted in either the Q/LAIV or placebo group (Table 6). The only TEAE reported at a rate ≥5% was nasopharyngitis: 8.1% (70/868) of subjects in the Q/LAIV group and 8.3% (36/433) of subjects in the placebo group, and no febrile convulsions were reported. SAEs were reported in 3 (0.3%) subjects in the Q/LAIV group and 3 (0.7%) subjects in the placebo group. The SAEs reported in the Q/LAIV group were periton-sillar abscess, convulsion, and appendicitis, and they occurred at 112, 115, and 134 days post-vaccination, respectively, while SAEs reported in the placebo group were pneumonia, osteochondrosis, and hydronephrosis. All SAEs were considered to be unrelated to receipt of the IP.

### Table 4
Solicited symptoms observed among the safety population (Study 2; aged 7-18 y)

| Symptom                                | Q/LAIV (n = 868) | Placebo (n = 433) | Rate difference point estimate (95% CI) |
|----------------------------------------|-----------------|-------------------|---------------------------------------|
| Number of subjects with any solicited symptoms, n (%) | 362 (41.7) | 176 (40.6) | 1.1 (−4.7, 6.7)                          |
| Runny/stuffy nose                      | 288 (33.2) | 120 (27.7) | 5.5 (0.1, 10.6)                          |
| Cough                                  | 108 (12.4) | 69 (15.9)  | −3.5 (−7.8, 0.4)                          |
| Sore throat                            | 88 (10.1)  | 61 (14.1)  | −3.9 (−8.0, −0.3)                        |
| Headache                               | 83 (9.6)   | 37 (8.5)   | 1.0 (−2.5, 4.2)                          |
| Decreased activity level (lethargy) OR tiredness/weaknesses | 37 (4.3) | 11 (2.5) | 1.7 (−0.6, 3.7)                          |
| Temperature (fever ≥ 100.4°F [38.0°C] by any route) | 26 (3.0) | 12 (2.8) | 0.2 (−2.0, 2.1)                          |
| Decreased appetite                     | 20 (2.3)  | 10 (2.3)   | 0.0 (−2.1, 1.6)                          |
| Generalized muscle aches               | 9 (1.0)    | 2 (0.5)    | 0.6 (−0.8, 1.6)                          |

CI, confidence interval; Q/LAIV, quadrivalent live attenuated influenza vaccine.

*A subject with at least 1 solicited symptom was counted once.

### Table 5
Overview of treatment-emergent adverse events (TEAEs) among the safety population (Study 1; aged 2-6 y)

| Description                                    | After 1st dose (n = 100) | After 2nd dose (n = 6) |
|------------------------------------------------|--------------------------|------------------------|
| Number of subjects with                        |                          |                        |
| At least 1 TEAE, n (%)                         | 42 (42.0)                | 2 (33.3)               |
| At least 1 TEAE related to the IP, n (%)a       | 1 (1.0)                  | 0 (0.0)                |
| At least 1 treatment-emergent SAE, n (%)       | 0 (0.0)                  | 0 (0.0)                |
| At least 1 treatment-emergent SAE related to the IP, n (%) | 0 (0.0) | 0 (0.0) |
| At least 1 SAE, n (%)                          | 0 (0.0)                  | 0 (0.0)                |
| A TEAE leading to study discontinuation, n (%) | 0 (0.0)                  | 0 (0.0)                |
| A TEAE leading to death, n (%)                 | 0 (0.0)                  | 0 (0.0)                |
| Intensity of TEAE                              |                          |                        |
| Mild, n (%)                                     | 42 (42.0)                | 2 (33.3)               |
| Moderate, n (%)                                 | 0 (0.0)                  | 0 (0.0)                |
| Severe, n (%)                                   | 0 (0.0)                  | 0 (0.0)                |

IP, investigational product; Q/LAIV, quadrivalent live attenuated influenza vaccine; SAE, serious adverse event.

*Two TEAEs, abdominal pain, and diarrhea were reported after the first dose by 1 subject.

### 3.4 Efficacy

In Study 2, in the PP population, swab samples for genotyping, subtyping, and sequencing were collected from 532 subjects (62.7%) in the MEDI3250 group and from 299 subjects (69.5%) in the placebo group through the end of the 2014-2015 influenza season. Swab samples were collected at least 14 days after vaccination for 513 subjects (60.4%) and 288 subjects (67.0%), respectively. Among the PP population, influenza caused by vaccine-matched strains based on the definition of mCDC-ILI was reported in one of 430 subjects (0.2%) in the placebo group. The subject was infected with a B/Yamagata lineage strain, which resulted in a vaccine efficacy estimate of 100% (95% CI: −1875.3, 100.0; Table 7). Among the PP population, the incidence of influenza caused by any strain regardless of match to the vaccine based on the definition of mCDC-ILI was 19.9% (169/849 subjects) in the Q/LAIV group and 27.4% (118/430) in the placebo group. The estimate of vaccine efficacy for any strain regardless of match to the vaccine was 27.5% (95% CI: 7.4, 43.0) (Table 7). Vaccine efficacy for all strains regardless of match by age group was 22.9% (95% CI: −19.0, 49.5) for children aged 7-8 years and 30.2% (95% CI: 5.6, 48.1) for children aged 9-18 years. The vast majority strains (275/287) that circulated during the study were H3N2 strains that were significantly mismatched to the vaccine H3N2 strain. For these strains, the vaccine had an efficacy estimate of 26.3% (95% CI: 5.4, 42.4) (Table 7).
DISCUSSION

Children are at high risk of influenza infection compared with other age groups and play an important role in spreading influenza in the community. The benefit of vaccinating children against influenza is twofold: a direct reduction of morbidity and mortality in the pediatric population, which can also extend to the community around them through reduced rates of secondary transmission.

In these first studies of the safety and efficacy of Q/LAIV in Japanese children, Q/LAIV was generally well tolerated, and the incidence of solicited symptoms and adverse events was similar to those observed in studies conducted outside of Japan. The safety of
trivalent LAIV in children 2 years of age and older has been well established in over 70 studies enrolling more than 140,000 subjects and through company-sponsored post-marketing safety surveillance of the more than 60 million doses distributed since initial approval of the vaccine in 2003. Similarly, the safety of the quadrivalent formulation of the vaccine in children 2 years of age and older has been well established through studies enrolling over 60,000 subjects and through company-sponsored post-marketing safety surveillance of the more than 50 million doses distributed since initial approval of quadrivalent LAIV in 2012.

In terms of efficacy, Q/LAIV did not meet its primary endpoint of efficacy against matched strains, as only a single vaccine-matched strain from the B/Yamagata lineage was detected in the placebo group. The majority of influenza isolates detected during the study were mismatched A/H3N2 strains. However, the secondary endpoint of efficacy against any influenza strains regardless of match was met with statistically significant vaccine effectiveness of 27.5% (95% CI: 7.4, 43.0).

Similar to the experience in other countries, the 2014–2015 influenza season in Japan was characterized by the circulation of influenza A/H3N2 strains that were significantly mismatched (eightfold to 32-fold antigenic variation by ferret hemagglutination inhibition [HAI] antibody titers) to the strain selected by the World Health Organization and local health authorities for inclusion in both live attenuated and inactivated vaccines. While a higher level of efficacy (86%) was reported for LAIV against mismatched strains in a previous placebo-controlled study, it is worth noting that the degree of antigenic mismatch between the H3N2 strains in the study was small, fourfold by ferret HAI titers. The low level of vaccine efficacy observed in this study is consistent with LAIV efficacy reported in other randomized trials in which significantly mismatched (>8-fold by ferret HAI titers) A/H3N2 strains circulated. In these studies, vaccine efficacy estimates compared to placebo for significantly mismatched H3N2 strains were 18% and 31% and data interpretation lies with the authors.

5 | CONCLUSIONS

The two phase 3 studies reported here provide the first assessment of the safety and efficacy of Q/LAIV in Japanese children. Q/LAIV was found to be generally well tolerated in the Japanese pediatric population 2 through 18 years of age, and the safety profile was comparable to that observed in studies conducted outside of Japan. Observed efficacy was low, due to the predominance of circulating strains that were highly mismatched to the vaccine during the 2014-2015 season. Consequently, the study did not meet its primary efficacy endpoint, efficacy against matched strains, as only a single vaccine-matched strain was reported during the study. However, the secondary endpoint of efficacy against all strains regardless of match was met, and the results were consistent with LAIV efficacy observed in previous randomized trials in which significantly mismatched A/H3N2 strains circulated.

ACKNOWLEDGEMENTS

The authors would like to thank the patients, their families, the investigators, and the members of the Independent Data Monitoring Committee involved in these studies. Medical writing support, including developing outline and initial draft and incorporation of comments, was provided by Abby Armitt, MSc, and Talya Underwood MPhil (Cantab), and editorial support, including formatting, proofreading, and submission, was provided by Sinead Stewart, all of Prime Global, Knutsford, UK, supported by AstraZeneca according to Good Publication Practice guidelines (http://annals.org/aim/fullarticle/2424869/good-publication-practice-communicating-company-sponsored-medical-research-gpp3). The Sponsor was involved in the study design, collection, analysis, and interpretation of data, as well as data checking of information provided in the manuscript. However, ultimate responsibility for opinions, conclusions, and data interpretation lies with the authors.

CONFLICT OF INTEREST

Raburn Mallory, Jing Yu, and Filip Dubovsky are employees and shareholders of MedImmune. Sachiko Kameo, Michio Tanaka, and Yohji Itoh are employees and shareholders of AstraZeneca Japan. Ki Rito was an employee of AstraZeneca during this study.
REFERENCES

1. World Health Organization. Seasonal Influenza. Last updated. http://www.who.int/ith/diseases/influenza_seasonal/en/. Accessed February 15, 2017.
2. Zaraket H, Saito R. Japanese surveillance systems and treatment for influenza. Curr Treat Options Infect Dis. 2016;8:311-328.
3. World Health Organization. Influenza. Last updated. http://www.who.int/immunization/topics/influenza/en/. Accessed April 7, 2017.
4. Centers for Disease Control and Prevention. People at High Risk of Developing Flu-Related Complications. Last updated 25th August 2017. https://www.cdc.gov/flu/about/disease/high_risk.htm. Accessed March 2, 2017.
5. Lafond KE, Nair H, Rasooly MH, et al. Global role and burden of influenza in pediatric respiratory hospitalizations, 1982-2012: a systematic analysis. PLoS Med. 2016;13:e1001977.
6. Usonis V, Anca I, Andre F, et al. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children. BMC Infect Dis. 2010;10:168.
7. Bell D, Nicoll A, Fukuda K, et al. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006;12:81-87.
8. World Health Organization Writing Group. Nonpharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006;12:81-87.
9. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8:81-88.
10. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30:1993-1998.
11. Public Health England. The National Childhood Flu Immunisation Programme 2016/17: Information for healthcare practitioners. Last updated. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/551676/Childhood_flu_programme_information_for_healthcare_practitioners.pdf. Accessed February 16, 2017.
12. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intransal influenza virus vaccine in children. N Engl J Med. 1998;338:1405-1412.
13. Tam JS, Capeding MR, Lum LC, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J. 2007;26:619-628.
14. Vesikari T, Fleming DM, Aristegui JF, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics. 2006;118:2298-2312.
15. Ambrose CS, Antonova EN. The healthcare and societal burden associated with influenza in vaccinated and unvaccinated European and Israeli children. Eur J Clin Microbiol Infect Dis. 2014;33:569-575.
16. European Medicines Agency. Fluenz Tetra nasal spray suspension summary of product characteristics. Last updated. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002617/WC500158412.pdf. Accessed November 6, 2017.
17. AstraZeneca. Flumist Quadrivalent Product Monography. Last updated. https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/flumist-qlaiv-product-monograph-en.pdf. Accessed November 6, 2017.
18. Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001;344:889-896.
19. Ambrose CS, Yi T, Falloon J. An integrated, multidatabase analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respir Viruses. 2011;5:389-397.
20. Block SL, Falloon J, Hirschfield JA, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J. 2012;31:745-751.
21. Baxter R, Eaton A, Hansen J, et al. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49 years. Vaccine. 2017;35:1254-1258.
22. Xie H, Wan XF, Ye Z, et al. H3N2 mismatch of 2014-15 Northern hemisphere influenza viruses and head-to-head comparison between human and ferret anti sera derived antigenic maps. Sci Rep. 2015;5:15279.
23. Centers for Disease Control and Prevention. What You Should Know for the 2014-2015 Influenza Season. Last updated 18th February 2016. https://www.cdc.gov/flu/pastseasons/1415season.htm. Accessed March 2, 2017.
24. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168-175.
25. Flannery B, Clippard J. Updated interim influenza vaccine effectiveness estimates by age group and vaccine type for the 2014-15 season: Updates from the US Influenza Vaccine Effectiveness (Flu VE) Network. Last updated. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-02/flu-01-Flannery.pdf. Accessed November 6, 2017.
26. Klick B, Durrani S, Chan KH, et al. Live attenuated seasonal and pandemic influenza vaccine in school-age children: a randomized controlled trial. Vaccine. 2013;31:1937-1943.
27. Lum LC, Borja-Tabora CF, Breiman RF, et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine. 2010;28:1566-1574.
28. Caspard H, Mallory R, Yu H, Ambrose CS. Live attenuated influenza vaccine effectiveness in children from 2009 through 2015-2016: a meta-analysis. Open Forum Infect Dis. 2017;4:oxf111.
29. Pebody R, Warburton F, Andrews N, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill. 2015;20. https://doi.org/10.2807/1560-7917.ES.2015.20.36.30013.
30. Skowronski DM, Chambers C, Sabaiduc S, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20:21022.
31. Sugaya N, Shinjo M, Kawakami C, et al. Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan. Euro Surveill. 2016;21. https://doi.org/10.2807/1560-7917.ES.2016.21.42.30377.

How to cite this article: Mallory RM, Yu J, Kameo S, et al. The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: Results of two phase 3 studies. Influenza Other Respir Viruses. 2018;12:438-445. https://doi.org/10.1111/irv.12555